Psoriatic Arthritis: EULAR 2026 Recap Save

I. THE HEAD-TO-HEAD ERA ARRIVES IN PSA

Rheumatologists have been debating IL-17 vs. IL-23 inhibition in PsA for years — mostly on theory, market data, and cross-trial comparisons that are notoriously unreliable. EULAR 2026 finally produced the head-to-head data the field needed. BE BOLD put bimekizumab against risankizumab in active PsA, and the result was clear : the dual IL-17A/F inhibitor won on joints (ACR50) while skin and other secondary outcomes were similar at weeks 16 and 25. 

BE BOLD: Going Where No PsA Trial Has Gone Before

What's New in Psoriatic Arthritis: A Whirlwind Tour

Guselkumab Delivers Across the PsA Disease Spectrum: APEX Trial

Debate: Combination Therapies for Inflammatory Arthritis?

PsA Topic Podcast Compilation

Conclusions:

BE BOLD is the trial PsA needed. Bimekizumab (dual IL-17A/F inhibition) beat risankizumab (IL-23 inhibition) head-to-head in 553 patients with active PsA: ACR50 49% vs. 38% at week 16, and was still significant at week 24 (55% vs. 44%). Secondary musculoskeletal and skin endpoints were numerically better (but not significant) with bimekizumab throughout.. The field now has head-to-head evidence, a growing menu of proven agents across pathways, and no shortage of patients who haven't responded adequately to any of them. The next frontier, as McGonagle outlined, is biologically refractory disease — defining it rigorously and designing combination strategies for it. The debate on combination therapy is no longer theoretical.

II. OBESITY, GLP-1s, AND DIET IN PsA 

More than 70% of PsA patients carry excess weight — and EULAR 2026 made a persuasive case that this is not merely a comorbidity problem but a disease-biology problem. The TOGETHER PsA trial tested ixekizumab plus tirzepatide against ixekizumab alone, and the results were striking enough that patients will be asking about this combo before most rheumatologists have had a chance to read the paper. At the same time, dietary data added nuance: not all lifestyle interventions are created equal, and the CRP doesn't lie.

Beyond the Scale: Do GLP-1RAs Offer More Than Weight Loss in PsA?

BMI Outranks Treatment in PsA Outcomes?

Diet as a DMARD? The Evidence Is Still Hard to Swallow

Dietary Interventions in PsA

PsA Topic Panel: EULAR 2026

Conclusions:

TOGETHER PsA randomized overweight and obese PsA patients (mean BMI 38) to ixekizumab plus tirzepatide vs. ixekizumab alone, and the combined primary endpoint ( ACR50 plus ≥10% weight loss at week 36) was achieved in 35% of the combination group versus near zero in the IL-17 alone arm. The ACR50 alone was also significantly better with combination therapy, and the CRP reduction was the most dramatic and unconfoundable finding: you cannot placebo your way to a lower CRP. This is biology, not expectation bias. At the same time, the dietary data from DIPSA offered a more measured message: Mediterranean and calorie-restricted DASH diets both reduced disease activity in PsA compared to standard advice, but effect sizes were modest and durability uncertain. The implications are consistent — weight and metabolic status are active participants in PsA disease biology, not innocent bystanders. Rheumatologists who build a clear pathway to GLP-1 access for eligible PsA patients, whether through their own practice or a weight management specialist, will deliver meaningfully better outcomes. That window is open now.

III. CATCHING PsA BEFORE IT STARTS

One of the most consequential questions in psoriatic disease is whether we can intervene before PsA is established — either by identifying which psoriasis patients are on the path to arthritis or by selecting biologics that may actually reduce transition risk. EULAR 2026 offered new data on both fronts, and subclinical PsA is emerging as a serious clinical construct, not just a research curiosity.

Synovio-entheseal inflammation and the tipping point from PsO to PsA

Biologic Class Determines PsA Risk in Psoriasis

Can We Stop PsA Before it Starts?

Transition from Psoriasis to Psoriatic Arthritis

Imaging in Subclinical Psoriatic Arthritis

Conclusions:

Subclinical PsA — psoriasis with arthralgia and imaging abnormalities but no clinically evident arthritis — is no longer just a research definition. It is a clinical opportunity. The synovio-entheseal data showed that subclinical inflammatory processes are frequently underway months before joint disease becomes apparent, and that imaging can detect them. The biologic class data from Kougkas and colleagues was even more provocative: in a real-world cohort followed for up to 17 years, patients with psoriasis treated with non-TNFi biologics had a significantly lower incidence of PsA than those on TNFi — raising the possibility that mechanism of action influences disease trajectory, not just skin clearance. This does not yet warrant changing prescribing practices in dermatology, but it is exactly the kind of signal that rheumatology-dermatology joint clinics should be tracking. The message for practicing rheumatologists: psoriasis patients with extensive skin disease or musculoskeletal symptoms or imaging findings deserve early referral, and the question of which biologic a dermatologist chooses may matter for joints and not just skin outcomes.

IV. THE PAIN THAT TREATMENT DOESN'T FIX 

Even well-controlled PsA leaves some patients in pain. EULAR 2026 put a spotlight on the dimensions of PsA that standard disease activity scores were never designed to capture: nociplastic and neuropathic-like pain, the impact of the menopausal transition on disease phenotype, and the complex role of synovial biopsy in guiding therapy in refractory disease. These are the patients most likely to be sitting in your clinic next week, still not doing well, and the field is finally taking them seriously.

The Pain that Inflammation Does Not Explain in SpA and PsA

Hot Topic: Menopause and Inflammatory Arthritis Outcomes in RA and PsA

Synovial Biopsy Guided Therapy Improves Clinical Outcomes in PsA

The Case for Dual Pathway Blockade in Refractory PsA

EULAR 2026 Daily Podcast Day 3a

Conclusions:

The NEUPIA study captured something clinicians see constantly but the literature rarely names cleanly: neuropathic-like and nociplastic pain in PsA patients whose inflammatory markers are controlled. When the ASDAS is low, the CRP is normal, and the joints look quiet — but the patient still hurts — the problem is not a missed biologic opportunity. It is a different mechanism entirely, and switching therapies will not fix it. Menopause adds another layer: postmenopausal women with PsA present with more severe radiographic damage and have different biologic response profiles than premenopausal patients, a signal that has been underappreciated in trial populations skewed toward younger patients. Meanwhile, synovial biopsy-guided therapy in refractory PsA showed that tissue phenotyping can improve outcomes in a subset of patients — though the sample sizes remain small and the practice is not yet scalable. Taken together, this cluster is about the limits of the treat-to-target paradigm as currently practiced. Targeting inflammation is necessary but not sufficient for a meaningful proportion of PsA patients, and the field needs better tools to identify who needs what beyond the next biologic switch.